Revenue $4.14B, down 0.8% on a year earlier. Respiratory Products Revenue $58.00M, up 5.5%. Anda Revenue $413.00M, up 13.2%. Diluted EPS -$0.49 against $0.24.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $4.14B | $3.98B | $4.18B | -0.8% |
| Operating income | -$231.00M | $652.00M | $455.00M | -150.8% |
| Net income | -$575.00M | $369.00M | $283.00M | -303.2% |
| Diluted EPS | -$0.49 | $0.31 | $0.24 | |
| Operating cash flow | $411.00M | -$40.00M | $227.00M | +81.1% |
| Capital expenditures | -$104.00M | -$168.00M | -$96.00M | |
| Free cash flow | $307.00M | -$208.00M | $131.00M | +134.4% |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Respiratory Products Revenue | $58.00M | $55.00M | +5.5% |
| Anda Revenue | $413.00M | $365.00M | +13.2% |
| Europe segment revenues | $1.26B | $1.30B | -2.7% |
| Generic products revenues | $660.00M | $410.00M | +61.0% |
| International Markets segment revenues | $550.00M | $495.00M | +11.1% |
| North America segment revenues | $1.70B | $2.15B | -20.9% |
| Revenues Growth | -1% | -1% | |
| UZEDY Revenues | $77.00M | $54.00M | +42.6% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Teva Pharmaceutical Industries (TEVA) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/TEVA/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
